Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma

A child near death with an ALK-fusion–positive high-grade glioma refractory to standard treatment had a dramatic response when treatment with lorlatinib was begun. The drug was stopped once the child had an apparent complete remission, but treatment with lorlatinib resumed when relapse occurred 6 mo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-08, Vol.385 (8), p.761-763
Hauptverfasser:	Bagchi, Aditi, Orr, Brent A, Campagne, Olivia, Dhanda, Sandeep, Nair, Sreenath, Tran, Quynh, Christensen, Anthony M, Gajjar, Amar, Furtado, Larissa V, Vasilyeva, Aksana, Boop, Frederick, Stewart, Clinton, Robinson, Giles W
Format:	Artikel
Sprache:	eng
Schlagworte:	Aminopyridines Anaplastic Lymphoma Kinase - antagonists & inhibitors Brain Neoplasms - diagnostic imaging Brain Neoplasms - drug therapy Brain Neoplasms - pathology Brain Neoplasms - surgery Brain Tumor Cancer therapies Chemotherapy Child, Preschool Childhood Cancer Childhood Diseases Combined Modality Therapy Glioma Glioma - diagnostic imaging Glioma - drug therapy Glioma - pathology Glioma - surgery Hematology Humans Lactams Lactams, Macrocyclic - therapeutic use Magnetic Resonance Imaging Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Nervous system Neurology Neurosurgery Oncology Pediatrics Pyrazoles Radiation Remission Remission Induction Surgery Surgical outcomes Treatments in Oncology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A child near death with an ALK-fusion–positive high-grade glioma refractory to standard treatment had a dramatic response when treatment with lorlatinib was begun. The drug was stopped once the child had an apparent complete remission, but treatment with lorlatinib resumed when relapse occurred 6 months later. At this time, the child is attending preschool and has normal neurologic function.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc2101264